Hemodynamic Effects of Fenofibrate and Coenzyme Q₁₀ in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction
OBJECTIVE:--To investigate the effects of fenofibrate and coenzyme Q₁₀ (CoQ) on diastolic function, ambulatory blood pressure (ABP), and heart rate (HR) in type 2 diabetic subjects with left ventricular diastolic dysfunction (LVDD). RESEARCH DESIGN AND METHODS--We randomized, double-blind, 74 subjec...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2008-08, Vol.31 (8), p.1502-1509 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1509 |
|---|---|
| container_issue | 8 |
| container_start_page | 1502 |
| container_title | Diabetes care |
| container_volume | 31 |
| creator | Chew, Gerard T Watts, Gerald F Davis, Timothy M.E Stuckey, Bronwyn G.A Beilin, Lawrence J Thompson, Peter L Burke, Valerie Currie, Philip J |
| description | OBJECTIVE:--To investigate the effects of fenofibrate and coenzyme Q₁₀ (CoQ) on diastolic function, ambulatory blood pressure (ABP), and heart rate (HR) in type 2 diabetic subjects with left ventricular diastolic dysfunction (LVDD). RESEARCH DESIGN AND METHODS--We randomized, double-blind, 74 subjects to fenofibrate 160 mg daily, CoQ 200 mg daily, fenofibrate 160 mg plus CoQ 200 mg daily, or matching placebo for 6 months. Echocardiography (including tissue Doppler imaging) and 24-h ABP and HR monitoring were performed pre- and postintervention. RESULTS:--Neither fenofibrate nor CoQ, alone or in combination, altered early diastolic mitral annular myocardial relaxation velocity (E'), early-to-late mitral inflow velocity ratio (E/A), deceleration time, isovolumic relaxation time, or the ratio of early mitral flow velocity to early diastolic mitral annular myocardial relaxation velocity (E/E') compared with placebo (P > 0.05). Fenofibrate and CoQ interactively (P = 0.001) lowered 24-h systolic blood pressure (-3.4 ± 0.09 mmHg, P = 0.010), with a prominent nocturnal effect (-5.7 ± 1.5 mmHg, P = 0.006). Fenofibrate (-1.3 ± 0.5 mmHg, P = 0.013) and CoQ (-2.2 ± 0.5 mmHg, P < 0.001) independently lowered 24-h diastolic blood pressure. Fenofibrate reduced 24-h HR (-3.3 ± 0.5 beats/min, P < 0.001), but CoQ had no effect on HR. CONCLUSIONS:--In type 2 diabetic subjects with LVDD, neither fenofibrate nor CoQ, alone or in combination, improved diastolic function significantly. However, fenofibrate and CoQ independently and interactively lowered 24-h blood pressure, and fenofibrate alone reduced 24-h HR. |
| doi_str_mv | 10.2337/dc08-0118 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2337_dc08_0118</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69360913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3778-ba7a1e63151d08c5012b7beb841671412da77cb61bc0177ac4c79e78b355e76e3</originalsourceid><addsrcrecordid>eNpVkc9u1DAQhyMEokvhwAuALyCBFPC_xM4FCW1birQSQm3haNnOZNdVYm_tBBQuQB-1T0LSXRU42fJ885uxvix7SvAbyph4W1ssc0yIvJctSMWKvCi4vJ8tMOFVXlQVPcgepXSJMeZcyofZAZFcCi7xIvt5Cl2oR687Z9Fx04DtEwoNOgEfGmei7gFpX6NlAP9j7AB9vrn-fXP9CzmPzsctIIqOnDbQT-1ng7m87f_q-g1aQdOjL-D76OzQ6jhzqQ_tBB6NqRm87V3wj7MHjW4TPNmfh9nFyfH58jRfffrwcfl-lVsmhMyNFppAyUhBaixtgQk1woCRnJSCcEJrLYQ1JTEWEyG05VZUIKRhRQGiBHaYvdvlbgfTQW3nvXSrttF1Oo4qaKf-r3i3UevwTVFe8bKgU8DLfUAMVwOkXnUuWWhb7SEMSZUVK3FF2AS-2oE2hpQiNHdDCFazLjXrUrOuiX3271Z_yb2fCXixB3Syum2i9talO26KKygv56Gvd9zGrTffXQRV31qBNF-snh4YUVKRAs9feb6DGx2UXscp8OKMYsIwrijGjLI_efG36w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69360913</pqid></control><display><type>article</type><title>Hemodynamic Effects of Fenofibrate and Coenzyme Q₁₀ in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Chew, Gerard T ; Watts, Gerald F ; Davis, Timothy M.E ; Stuckey, Bronwyn G.A ; Beilin, Lawrence J ; Thompson, Peter L ; Burke, Valerie ; Currie, Philip J</creator><creatorcontrib>Chew, Gerard T ; Watts, Gerald F ; Davis, Timothy M.E ; Stuckey, Bronwyn G.A ; Beilin, Lawrence J ; Thompson, Peter L ; Burke, Valerie ; Currie, Philip J</creatorcontrib><description>OBJECTIVE:--To investigate the effects of fenofibrate and coenzyme Q₁₀ (CoQ) on diastolic function, ambulatory blood pressure (ABP), and heart rate (HR) in type 2 diabetic subjects with left ventricular diastolic dysfunction (LVDD). RESEARCH DESIGN AND METHODS--We randomized, double-blind, 74 subjects to fenofibrate 160 mg daily, CoQ 200 mg daily, fenofibrate 160 mg plus CoQ 200 mg daily, or matching placebo for 6 months. Echocardiography (including tissue Doppler imaging) and 24-h ABP and HR monitoring were performed pre- and postintervention. RESULTS:--Neither fenofibrate nor CoQ, alone or in combination, altered early diastolic mitral annular myocardial relaxation velocity (E'), early-to-late mitral inflow velocity ratio (E/A), deceleration time, isovolumic relaxation time, or the ratio of early mitral flow velocity to early diastolic mitral annular myocardial relaxation velocity (E/E') compared with placebo (P > 0.05). Fenofibrate and CoQ interactively (P = 0.001) lowered 24-h systolic blood pressure (-3.4 ± 0.09 mmHg, P = 0.010), with a prominent nocturnal effect (-5.7 ± 1.5 mmHg, P = 0.006). Fenofibrate (-1.3 ± 0.5 mmHg, P = 0.013) and CoQ (-2.2 ± 0.5 mmHg, P < 0.001) independently lowered 24-h diastolic blood pressure. Fenofibrate reduced 24-h HR (-3.3 ± 0.5 beats/min, P < 0.001), but CoQ had no effect on HR. CONCLUSIONS:--In type 2 diabetic subjects with LVDD, neither fenofibrate nor CoQ, alone or in combination, improved diastolic function significantly. However, fenofibrate and CoQ independently and interactively lowered 24-h blood pressure, and fenofibrate alone reduced 24-h HR.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc08-0118</identifier><identifier>PMID: 18487480</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Blood Pressure - drug effects ; Blood Pressure Monitoring, Ambulatory ; Clinical Care/Education/Nutrition/Psychosocial Research ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - blood ; Diabetic Angiopathies - diagnostic imaging ; Diastole - drug effects ; Double-Blind Method ; Echocardiography ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Fenofibrate - pharmacology ; Fenofibrate - therapeutic use ; Heart Rate ; Humans ; Hypolipidemic Agents - therapeutic use ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Miscellaneous ; Placebos ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Ubiquinone - analogs & derivatives ; Ubiquinone - pharmacology ; Ubiquinone - therapeutic use ; Ventricular Dysfunction, Left - blood ; Ventricular Dysfunction, Left - diagnostic imaging</subject><ispartof>Diabetes care, 2008-08, Vol.31 (8), p.1502-1509</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2008, American Diabetes Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3778-ba7a1e63151d08c5012b7beb841671412da77cb61bc0177ac4c79e78b355e76e3</citedby><cites>FETCH-LOGICAL-c3778-ba7a1e63151d08c5012b7beb841671412da77cb61bc0177ac4c79e78b355e76e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23352463$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18487480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chew, Gerard T</creatorcontrib><creatorcontrib>Watts, Gerald F</creatorcontrib><creatorcontrib>Davis, Timothy M.E</creatorcontrib><creatorcontrib>Stuckey, Bronwyn G.A</creatorcontrib><creatorcontrib>Beilin, Lawrence J</creatorcontrib><creatorcontrib>Thompson, Peter L</creatorcontrib><creatorcontrib>Burke, Valerie</creatorcontrib><creatorcontrib>Currie, Philip J</creatorcontrib><title>Hemodynamic Effects of Fenofibrate and Coenzyme Q₁₀ in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE:--To investigate the effects of fenofibrate and coenzyme Q₁₀ (CoQ) on diastolic function, ambulatory blood pressure (ABP), and heart rate (HR) in type 2 diabetic subjects with left ventricular diastolic dysfunction (LVDD). RESEARCH DESIGN AND METHODS--We randomized, double-blind, 74 subjects to fenofibrate 160 mg daily, CoQ 200 mg daily, fenofibrate 160 mg plus CoQ 200 mg daily, or matching placebo for 6 months. Echocardiography (including tissue Doppler imaging) and 24-h ABP and HR monitoring were performed pre- and postintervention. RESULTS:--Neither fenofibrate nor CoQ, alone or in combination, altered early diastolic mitral annular myocardial relaxation velocity (E'), early-to-late mitral inflow velocity ratio (E/A), deceleration time, isovolumic relaxation time, or the ratio of early mitral flow velocity to early diastolic mitral annular myocardial relaxation velocity (E/E') compared with placebo (P > 0.05). Fenofibrate and CoQ interactively (P = 0.001) lowered 24-h systolic blood pressure (-3.4 ± 0.09 mmHg, P = 0.010), with a prominent nocturnal effect (-5.7 ± 1.5 mmHg, P = 0.006). Fenofibrate (-1.3 ± 0.5 mmHg, P = 0.013) and CoQ (-2.2 ± 0.5 mmHg, P < 0.001) independently lowered 24-h diastolic blood pressure. Fenofibrate reduced 24-h HR (-3.3 ± 0.5 beats/min, P < 0.001), but CoQ had no effect on HR. CONCLUSIONS:--In type 2 diabetic subjects with LVDD, neither fenofibrate nor CoQ, alone or in combination, improved diastolic function significantly. However, fenofibrate and CoQ independently and interactively lowered 24-h blood pressure, and fenofibrate alone reduced 24-h HR.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure Monitoring, Ambulatory</subject><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Angiopathies - blood</subject><subject>Diabetic Angiopathies - diagnostic imaging</subject><subject>Diastole - drug effects</subject><subject>Double-Blind Method</subject><subject>Echocardiography</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Fenofibrate - pharmacology</subject><subject>Fenofibrate - therapeutic use</subject><subject>Heart Rate</subject><subject>Humans</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Placebos</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Ubiquinone - analogs & derivatives</subject><subject>Ubiquinone - pharmacology</subject><subject>Ubiquinone - therapeutic use</subject><subject>Ventricular Dysfunction, Left - blood</subject><subject>Ventricular Dysfunction, Left - diagnostic imaging</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc9u1DAQhyMEokvhwAuALyCBFPC_xM4FCW1birQSQm3haNnOZNdVYm_tBBQuQB-1T0LSXRU42fJ885uxvix7SvAbyph4W1ssc0yIvJctSMWKvCi4vJ8tMOFVXlQVPcgepXSJMeZcyofZAZFcCi7xIvt5Cl2oR687Z9Fx04DtEwoNOgEfGmei7gFpX6NlAP9j7AB9vrn-fXP9CzmPzsctIIqOnDbQT-1ng7m87f_q-g1aQdOjL-D76OzQ6jhzqQ_tBB6NqRm87V3wj7MHjW4TPNmfh9nFyfH58jRfffrwcfl-lVsmhMyNFppAyUhBaixtgQk1woCRnJSCcEJrLYQ1JTEWEyG05VZUIKRhRQGiBHaYvdvlbgfTQW3nvXSrttF1Oo4qaKf-r3i3UevwTVFe8bKgU8DLfUAMVwOkXnUuWWhb7SEMSZUVK3FF2AS-2oE2hpQiNHdDCFazLjXrUrOuiX3271Z_yb2fCXixB3Syum2i9talO26KKygv56Gvd9zGrTffXQRV31qBNF-snh4YUVKRAs9feb6DGx2UXscp8OKMYsIwrijGjLI_efG36w</recordid><startdate>200808</startdate><enddate>200808</enddate><creator>Chew, Gerard T</creator><creator>Watts, Gerald F</creator><creator>Davis, Timothy M.E</creator><creator>Stuckey, Bronwyn G.A</creator><creator>Beilin, Lawrence J</creator><creator>Thompson, Peter L</creator><creator>Burke, Valerie</creator><creator>Currie, Philip J</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200808</creationdate><title>Hemodynamic Effects of Fenofibrate and Coenzyme Q₁₀ in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction</title><author>Chew, Gerard T ; Watts, Gerald F ; Davis, Timothy M.E ; Stuckey, Bronwyn G.A ; Beilin, Lawrence J ; Thompson, Peter L ; Burke, Valerie ; Currie, Philip J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3778-ba7a1e63151d08c5012b7beb841671412da77cb61bc0177ac4c79e78b355e76e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure Monitoring, Ambulatory</topic><topic>Clinical Care/Education/Nutrition/Psychosocial Research</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Angiopathies - blood</topic><topic>Diabetic Angiopathies - diagnostic imaging</topic><topic>Diastole - drug effects</topic><topic>Double-Blind Method</topic><topic>Echocardiography</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Fenofibrate - pharmacology</topic><topic>Fenofibrate - therapeutic use</topic><topic>Heart Rate</topic><topic>Humans</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Placebos</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Ubiquinone - analogs & derivatives</topic><topic>Ubiquinone - pharmacology</topic><topic>Ubiquinone - therapeutic use</topic><topic>Ventricular Dysfunction, Left - blood</topic><topic>Ventricular Dysfunction, Left - diagnostic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chew, Gerard T</creatorcontrib><creatorcontrib>Watts, Gerald F</creatorcontrib><creatorcontrib>Davis, Timothy M.E</creatorcontrib><creatorcontrib>Stuckey, Bronwyn G.A</creatorcontrib><creatorcontrib>Beilin, Lawrence J</creatorcontrib><creatorcontrib>Thompson, Peter L</creatorcontrib><creatorcontrib>Burke, Valerie</creatorcontrib><creatorcontrib>Currie, Philip J</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chew, Gerard T</au><au>Watts, Gerald F</au><au>Davis, Timothy M.E</au><au>Stuckey, Bronwyn G.A</au><au>Beilin, Lawrence J</au><au>Thompson, Peter L</au><au>Burke, Valerie</au><au>Currie, Philip J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemodynamic Effects of Fenofibrate and Coenzyme Q₁₀ in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2008-08</date><risdate>2008</risdate><volume>31</volume><issue>8</issue><spage>1502</spage><epage>1509</epage><pages>1502-1509</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE:--To investigate the effects of fenofibrate and coenzyme Q₁₀ (CoQ) on diastolic function, ambulatory blood pressure (ABP), and heart rate (HR) in type 2 diabetic subjects with left ventricular diastolic dysfunction (LVDD). RESEARCH DESIGN AND METHODS--We randomized, double-blind, 74 subjects to fenofibrate 160 mg daily, CoQ 200 mg daily, fenofibrate 160 mg plus CoQ 200 mg daily, or matching placebo for 6 months. Echocardiography (including tissue Doppler imaging) and 24-h ABP and HR monitoring were performed pre- and postintervention. RESULTS:--Neither fenofibrate nor CoQ, alone or in combination, altered early diastolic mitral annular myocardial relaxation velocity (E'), early-to-late mitral inflow velocity ratio (E/A), deceleration time, isovolumic relaxation time, or the ratio of early mitral flow velocity to early diastolic mitral annular myocardial relaxation velocity (E/E') compared with placebo (P > 0.05). Fenofibrate and CoQ interactively (P = 0.001) lowered 24-h systolic blood pressure (-3.4 ± 0.09 mmHg, P = 0.010), with a prominent nocturnal effect (-5.7 ± 1.5 mmHg, P = 0.006). Fenofibrate (-1.3 ± 0.5 mmHg, P = 0.013) and CoQ (-2.2 ± 0.5 mmHg, P < 0.001) independently lowered 24-h diastolic blood pressure. Fenofibrate reduced 24-h HR (-3.3 ± 0.5 beats/min, P < 0.001), but CoQ had no effect on HR. CONCLUSIONS:--In type 2 diabetic subjects with LVDD, neither fenofibrate nor CoQ, alone or in combination, improved diastolic function significantly. However, fenofibrate and CoQ independently and interactively lowered 24-h blood pressure, and fenofibrate alone reduced 24-h HR.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>18487480</pmid><doi>10.2337/dc08-0118</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2008-08, Vol.31 (8), p.1502-1509 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_crossref_primary_10_2337_dc08_0118 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Biological and medical sciences Blood Pressure - drug effects Blood Pressure Monitoring, Ambulatory Clinical Care/Education/Nutrition/Psychosocial Research Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes. Impaired glucose tolerance Diabetic Angiopathies - blood Diabetic Angiopathies - diagnostic imaging Diastole - drug effects Double-Blind Method Echocardiography Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Fenofibrate - pharmacology Fenofibrate - therapeutic use Heart Rate Humans Hypolipidemic Agents - therapeutic use Male Medical sciences Metabolic diseases Middle Aged Miscellaneous Placebos Public health. Hygiene Public health. Hygiene-occupational medicine Ubiquinone - analogs & derivatives Ubiquinone - pharmacology Ubiquinone - therapeutic use Ventricular Dysfunction, Left - blood Ventricular Dysfunction, Left - diagnostic imaging |
| title | Hemodynamic Effects of Fenofibrate and Coenzyme Q₁₀ in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T03%3A39%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemodynamic%20Effects%20of%20Fenofibrate%20and%20Coenzyme%20Q%E2%82%81%E2%82%80%20in%20Type%202%20Diabetic%20Subjects%20With%20Left%20Ventricular%20Diastolic%20Dysfunction&rft.jtitle=Diabetes%20care&rft.au=Chew,%20Gerard%20T&rft.date=2008-08&rft.volume=31&rft.issue=8&rft.spage=1502&rft.epage=1509&rft.pages=1502-1509&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc08-0118&rft_dat=%3Cproquest_cross%3E69360913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69360913&rft_id=info:pmid/18487480&rfr_iscdi=true |